9 citations
,
May 2021 in “International Journal of Dermatology” In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.
December 2024 in “Journal of the European Academy of Dermatology and Venereology” This study found that both sublingual and oral minoxidil at 5 mg per day increased hair density similarly in men with androgenetic alopecia over 24 weeks, but sublingual administration was associated with fewer palpitations.
October 2024 in “Actas Dermo-Sifiliográficas” Sublingual minoxidil is safe and well-tolerated for hair loss treatment.
January 2026 in “Frontiers in Pharmacology” This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.
16 citations
,
May 2020 in “Journal of The European Academy of Dermatology and Venereology” This publication involves a case-series report on the treatment of male and female pattern hair loss using sublingual minoxidil in 64 patients, but it does not include an abstract or results.